Change Agents Corporation

AI-generated fair value estimate for this company.

Method: Blended net-asset and revenue-multiple valuation (no DCF): -$1.29M net tangible deficit (roughly $0.04M cash less $1.33M debt) offset by $0.39M FY2025 revenue across its several early commercial lines (KetoAir breathalyzer, AI video/content generation, Autonomous Air Defense counter-drone) valued at a conservative 5x trailing revenue ($1.95M) to capture some going-concern value beyond pure liquidation; net result of about $0.66M spread over 1.12M shares outstanding (post 1-for-20 reverse split).

Reasoning: With under $0.4M of revenue, a negative tangible-asset position, and a recent history of reverse splits and a Nasdaq compliance deficiency, a DCF would require fabricating a profitability path with no supporting evidence; a blended asset/revenue-multiple approach better reflects that the stock's worth rests on the embryonic, unproven nature of its diversified AI/health/defense pivots rather than on any established earnings power.